Scholarlink

<p>Mushrooms are highly valued as sources of novel bioactive molecules with therapeutic relevance. This study explored the potential of methanolic extract of <i>Rigidoporus ulmarius</i> (Sowerby) Imazeki using a combination of phytochemical, computational, and experimental approaches to evaluate its antidiabetic and anticancer activities. GC–MS analysis revealed a sterol-dominant profile, with ergosterol, ergosta-5,7-dien-3β-ol, α-ergostenol, and 9,11-dehydroprogesterone identified as the major metabolites. In silico study confirmed drug-likeness properties of compounds, while absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions suggested good gastrointestinal absorption, negligible mutagenicity, and low carcinogenic risk, though limited biodegradability was observed. Molecular docking revealed strong interactions of sterol derivatives (– 9.0 to − 10.2&#xa0;kcal/mol) with diabetes-related (α-amylase) and cancer-associated (Aurora-A, CDK1/Cks2, PLK1) targets. In vitro validation confirmed significant α-amylase inhibitory activity, with an IC<sub>50</sub> value of 0.85 ± 0.09&#xa0;mg/mL.The methanolic extract exhibited notable cytotoxic activity against 4T1 breast cancer cells, showing 71.28% growth inhibition at 1500&#xa0;µg/mL, with an IC<sub>50</sub> value of 721 ± 6&#xa0;µg/mL. Overall, <i>R. ulmarius</i> contains valuable sterol-based compounds with dual therapeutic potential against diabetes and cancer, which signify this mushroom as a potential lead for natural drug development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A multi-approach investigation of Rigidoporus ulmarius as a promising source of nutraceutical leads against diabetes and triple negative breast cancer

  • 期刊论文

  • 发表日期：

    2026年4月10日

查看全文
  • Chandrahas Dewangan,
  • Sakshi Agrawal,
  • Sushil Kumar Shahi

摘要

Mushrooms are highly valued as sources of novel bioactive molecules with therapeutic relevance. This study explored the potential of methanolic extract of Rigidoporus ulmarius (Sowerby) Imazeki using a combination of phytochemical, computational, and experimental approaches to evaluate its antidiabetic and anticancer activities. GC–MS analysis revealed a sterol-dominant profile, with ergosterol, ergosta-5,7-dien-3β-ol, α-ergostenol, and 9,11-dehydroprogesterone identified as the major metabolites. In silico study confirmed drug-likeness properties of compounds, while absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions suggested good gastrointestinal absorption, negligible mutagenicity, and low carcinogenic risk, though limited biodegradability was observed. Molecular docking revealed strong interactions of sterol derivatives (– 9.0 to − 10.2 kcal/mol) with diabetes-related (α-amylase) and cancer-associated (Aurora-A, CDK1/Cks2, PLK1) targets. In vitro validation confirmed significant α-amylase inhibitory activity, with an IC50 value of 0.85 ± 0.09 mg/mL.The methanolic extract exhibited notable cytotoxic activity against 4T1 breast cancer cells, showing 71.28% growth inhibition at 1500 µg/mL, with an IC50 value of 721 ± 6 µg/mL. Overall, R. ulmarius contains valuable sterol-based compounds with dual therapeutic potential against diabetes and cancer, which signify this mushroom as a potential lead for natural drug development.